Toxicology Papers of the Week

We investigated mechanisms underlying the clinical performance of a PD-L1×4-1BB bispecific antibody.

We evaluated whether the addition of programmed cell death protein 1 blockade to modified FOLFIRINOX improves outcomes compared with modified FOLFIRINOX alone. In this open-label, randomized phase II trial, patients with histologically confirmed BRPC or LAPC were randomly assigned (1:1) to receive modified FOLFIRINOX plus toripalimab (immunochemotherapy) or modified FOLFIRINOX alone (chemotherapy).

Here, we identify ADP-ribose, a neglected NAD catabolite generated by poly(ADP-ribose) polymerase 1 (PARP1) and poly(ADP-ribose) glycohydrolase, as an inducer of neuronal ferroptosis through nucleotide metabolic rewiring.

We integrated a pediatric cohort, multi-omics analyses, network toxicology, and animal experiments to investigate polyethylene (PE) microplastic exposure in ADHD vulnerability.

We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting.

We show that multi-site palmitoylation of TECR, redundantly catalyzed by the palmitoyl acyltransferases ZDHHC5 and ZDHHC2 and dynamically reversed by the depalmitoylase ABHD10, activates PERK-dependent ER stress signaling to trigger cell death.

This study investigated the anti-NSCLC effects of ALO using cell lines, patient-derived organoids, and mouse xenograft models.

We report post-hoc, exploratory analyses of patterns of disease progression.

We offer a framework for fast-acting next-generation FLT3 degraders that overcome resistance mechanisms to classical inhibitors.

We retrospectively analysed 643 men with M1 disease who began androgen-deprivation therapy during 2020-2026 at 23 Japanese institutions: CAB (113), abiraterone (139), enzalutamide (166), apalutamide (APA; 116), or TRI (109).

Here, we adapted and advanced a brain-restricted CAR T cell platform previously validated in glioblastoma to address the anatomical and biological challenges of DMG.

Overall, this study provides a platform for reducing the toxicity and enhancing the specificity of senotherapies necessary to advance their clinical development for treating chronic disease.

Here, we describe a single AAV vector encoding a compact adenine base editor, SlugABE8e, and a single-guide RNA, which enable efficient editing in a humanized DMD mouse model at a lower dose using the muscle-tropic MyoAAV4 capsid.

In this study, we explored the use of botulinum toxin (BTX) type A (incobotulinumtoxinA) plus transdermal scopolamine as a protective strategy to mitigate salivary gland uptake of PSMA radioligands.

In the DeLLphi-304 trial, at a median follow-up of <12 months, tarlatamab significantly improved overall survival (OS; P < 0.001), progression-free survival (PFS; P = 0.002), and patient-reported outcomes (PROs), and demonstrated a favorable safety profile versus chemotherapy.

This study presents three representative botanical extracts to illustrate practical tiered approaches for assessing their safety in cosmetic products.